Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivot Pharmaceuticals Inc  

(Public, OTCMKTS:PVOTF)   Watch this stock  
Find more results for OTC:NEUKF
+0.020 (15.38%)
Sep 19 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.13 - 0.16
52 week 0.02 - 0.16
Open 0.13
Vol / Avg. 37,500.00/6,000.00
Mkt cap 11.38M
P/E     -
Div/yield     -
EPS -0.03
Shares 75.85M
Beta -1.33
Inst. own     -

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.54% -5258.57%
Return on average equity - -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)

Website links


Pivot Pharmaceuticals Inc., formerly Neurokine Pharmaceuticals Inc., is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. The Company is in the business of developing and commercializing new uses for existing prescription drugs, as well as developing encapsulation technology in the treatment of neurodegenerative diseases. The Company's research and development activities are focused on advancing drug candidates for the treatment of women's cancers, including, but not limited to metastatic endometrial cancer and triple-negative breast cancer; leveraging drug delivery treatment options to allow targeted delivery of drugs to address women's health needs in urological and/or gynecological indications, and opportunistically in-licensing later-stage drug candidates to augment its drug pipeline.

Officers and directors

Ahmad Doroudian Ph.D. Chairman of the Board
Age: 51
Patrick Frankham Ph.D. Interim Chief Executive Officer, Vice President - Business Development, Director
Age: 43
Moira Ong Chief Financial Officer
Age: 40
Wolfgang Renz Ph.D. Director
Age: 47